BC subtypes appeared to be not strongly associated with newly identified TP53 mutations, and 3 of 11 patients showed subtype conversion (HR‐positive/HER2‐negative to TNBC; HER2‐enriched to HR‐positive/HER2‐negative; HR‐negative/HER2‐positive to TNBC; and then to HR‐negative/HER2‐positive). Here, ERBB2 is linked to breast cancer.